HemoBioTech signs research agreement with Texas Tech for blood substitute

By Lisa Kerner

Erie, Pa., Jan. 18 - HemoBioTech, Inc. signed a third stage Sponsored Research Agreement with Texas Tech University Health Sciences Center. The agreement will focus on the manufacture of clinical grade HemoTech, a chemically modified hemoglobin, according to a company news release.

HemoTech not only carries oxygen in the blood, but can also induce red blood cell production.

The agreement follows a second stage agreement between HemoBioTech and Texas Tech University Health Sciences Center which was completed in December. That agreement included the upgrade of the HemoTech production facility; creation of a bovine blood donor facility and preparation of new HemoTech patents.

"We are very pleased with the program at Texas Tech," Arthur P. Bollon, chairman and chief executive officer of HemoBioTech, said in the release. "We are now focusing on the manufacture of HemoTech which is needed for further expansion of the HemoTech program,"

Dallas-based HemoBioTech is engaged in the development of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.